We are a company limited by shares organized under the laws of the State of Israel. Our principal executive offices are located at 2 HaMa’ayan Street, Modi’in 7177871, Israel, and our telephone number is +972 (8) 642-9100. Following the entry into the collaboration with Hemispherian, we currently own 40% of Tetragon, the newly created company formed to develop GLIX1, with the remaining 60% owned by Hemispherian.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Biokine Therapeutics: in-license; Ayrmid License Agreement (November 2024): global rights ex-Asia, all indications other than solid tumors; Gloria License Agreement (October 2023): substantially all of Asia, all indications (planned motixafortide PDAC study in China not advancing on schedule)
Indications
Stem-cell mobilization for autologous transplantation in multiple myeloma(Approved)
Solid tumors(Stage not disclosed)
Status note FDA approved September 8, 2023 (with filgrastim). US commercialization shut down after November 2024 Ayrmid out-license; operations refocused on Israel development. AML indication discontinued; company still sees CXCR4 as viable in other AML lines.
GLIX1
Stage not disclosed · ActiveModality: small molecule (oral)
Target DNA damage response
Partnerships Hemispherian AS: September 2025 collaboration for development, clinical evaluation and commercialization; BioLineRx required to invest $5M in Tetragon Biosciences (GLIX1 vehicle) within 36 months or face equity reduction/repurchase
Indications
Glioblastoma (GBM)(Stage not disclosed)
Other solid tumors(Stage not disclosed)
Status note First-in-class oral small molecule targeting DNA damage response; no clinical trial disclosed in this filing.
Status note In-licensed candidate; no development status disclosed in this filing.
Per-asset detail extracted from the 20-F filed 2026-03-23. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.